Search

Your search keyword '"Rienk Offringa"' showing total 156 results

Search Constraints

Start Over You searched for: Author "Rienk Offringa" Remove constraint Author: "Rienk Offringa" Search Limiters Available in Library Collection Remove constraint Search Limiters: Available in Library Collection
156 results on '"Rienk Offringa"'

Search Results

1. T-Cell-Based Platform for Functional Screening of T-Cell Receptors Identified in Single-Cell RNA Sequencing Data Sets of Tumor-Infiltrating T-Cells

2. Identification of TRDV-TRAJ V domains in human and mouse T-cell receptor repertoires

3. Targeting the aryl hydrocarbon receptor (AhR) with BAY 2416964: a selective small molecule inhibitor for cancer immunotherapy

5. Secretogranin II influences the assembly and function of MHC class I in melanoma

6. T cell-mediated elimination of cancer cells by blocking CEACAM6–CEACAM1 interaction

7. Photon versus carbon ion irradiation: immunomodulatory effects exerted on murine tumor cell lines

8. Targeting immune-checkpoint inhibitor resistance mechanisms by MEK inhibitor and agonist anti-CD40 antibody combination therapy

9. The m6A-Related mRNA Signature Predicts the Prognosis of Pancreatic Cancer Patients

10. Novel Non-integrating DNA Nano-S/MAR Vectors Restore Gene Function in Isogenic Patient-Derived Pancreatic Tumor Models

11. Proimmunogenic impact of MEK inhibition synergizes with agonist anti-CD40 immunostimulatory antibodies in tumor therapy

12. p38 MAPK signaling in M1 macrophages results in selective elimination of M2 macrophages by MEK inhibition

13. Cancer Neoepitopes for Immunotherapy: Discordance Between Tumor-Infiltrating T Cell Reactivity and Tumor MHC Peptidome Display

14. Sensitization of Tumors for Attack by Virus-Specific CD8+ T-Cells Through Antibody-Mediated Delivery of Immunogenic T-Cell Epitopes

15. Optimized dendritic cell vaccination induces potent CD8 T cell responses and anti-tumor effects in transgenic mouse melanoma models

16. A high‐throughput RNAi screen for detection of immune‐checkpoint molecules that mediate tumor resistance to cytotoxic T lymphocytes

17. Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications

18. Human papillomavirus (HPV) upregulates the cellular deubiquitinase UCHL1 to suppress the keratinocyte's innate immune response.

19. Human papillomavirus deregulates the response of a cellular network comprising of chemotactic and proinflammatory genes.

20. Supplementary Table from Timed Ang2-Targeted Therapy Identifies the Angiopoietin–Tie Pathway as Key Regulator of Fatal Lymphogenous Metastasis

21. Supplementary Figures from Timed Ang2-Targeted Therapy Identifies the Angiopoietin–Tie Pathway as Key Regulator of Fatal Lymphogenous Metastasis

22. Data from Timed Ang2-Targeted Therapy Identifies the Angiopoietin–Tie Pathway as Key Regulator of Fatal Lymphogenous Metastasis

23. Supplementary Figure 3 from The Outcome of Ex Vivo TIL Expansion Is Highly Influenced by Spatial Heterogeneity of the Tumor T-Cell Repertoire and Differences in Intrinsic In Vitro Growth Capacity between T-Cell Clones

24. Data from The Outcome of Ex Vivo TIL Expansion Is Highly Influenced by Spatial Heterogeneity of the Tumor T-Cell Repertoire and Differences in Intrinsic In Vitro Growth Capacity between T-Cell Clones

25. Supplementary Figure 5 from The Outcome of Ex Vivo TIL Expansion Is Highly Influenced by Spatial Heterogeneity of the Tumor T-Cell Repertoire and Differences in Intrinsic In Vitro Growth Capacity between T-Cell Clones

26. Supplementary Figure 7 from The Outcome of Ex Vivo TIL Expansion Is Highly Influenced by Spatial Heterogeneity of the Tumor T-Cell Repertoire and Differences in Intrinsic In Vitro Growth Capacity between T-Cell Clones

27. Data from Prevailing Role of Contact Guidance in Intrastromal T-cell Trapping in Human Pancreatic Cancer

28. Supplementary Table 1 from The Outcome of Ex Vivo TIL Expansion Is Highly Influenced by Spatial Heterogeneity of the Tumor T-Cell Repertoire and Differences in Intrinsic In Vitro Growth Capacity between T-Cell Clones

29. Supplementary Figure 2 from The Outcome of Ex Vivo TIL Expansion Is Highly Influenced by Spatial Heterogeneity of the Tumor T-Cell Repertoire and Differences in Intrinsic In Vitro Growth Capacity between T-Cell Clones

30. Supplementary Figure 4 from The Outcome of Ex Vivo TIL Expansion Is Highly Influenced by Spatial Heterogeneity of the Tumor T-Cell Repertoire and Differences in Intrinsic In Vitro Growth Capacity between T-Cell Clones

31. Supplementary Figure 1 from Prevailing Role of Contact Guidance in Intrastromal T-cell Trapping in Human Pancreatic Cancer

32. Supplementary Methods from The Outcome of Ex Vivo TIL Expansion Is Highly Influenced by Spatial Heterogeneity of the Tumor T-Cell Repertoire and Differences in Intrinsic In Vitro Growth Capacity between T-Cell Clones

33. Supplementary Figure 1 from The Outcome of Ex Vivo TIL Expansion Is Highly Influenced by Spatial Heterogeneity of the Tumor T-Cell Repertoire and Differences in Intrinsic In Vitro Growth Capacity between T-Cell Clones

34. Supplementary Figure 2 from Prevailing Role of Contact Guidance in Intrastromal T-cell Trapping in Human Pancreatic Cancer

35. Supplementary Table 2 from The Outcome of Ex Vivo TIL Expansion Is Highly Influenced by Spatial Heterogeneity of the Tumor T-Cell Repertoire and Differences in Intrinsic In Vitro Growth Capacity between T-Cell Clones

36. Supplementary Figure Legends 1-6 from Design of Agonistic Altered Peptides for the Robust Induction of CTL Directed towards H-2Db in Complex with the Melanoma-Associated Epitope gp100

37. Supplementary Table 1 from Design of Agonistic Altered Peptides for the Robust Induction of CTL Directed towards H-2Db in Complex with the Melanoma-Associated Epitope gp100

38. Supplementary Figure 2 from Design of Agonistic Altered Peptides for the Robust Induction of CTL Directed towards H-2Db in Complex with the Melanoma-Associated Epitope gp100

39. Supplementary Figure 1 from Design of Agonistic Altered Peptides for the Robust Induction of CTL Directed towards H-2Db in Complex with the Melanoma-Associated Epitope gp100

40. Data from Design of Agonistic Altered Peptides for the Robust Induction of CTL Directed towards H-2Db in Complex with the Melanoma-Associated Epitope gp100

41. Supplementary Figure 3 from Design of Agonistic Altered Peptides for the Robust Induction of CTL Directed towards H-2Db in Complex with the Melanoma-Associated Epitope gp100

42. Supplementary Figure 4 from Design of Agonistic Altered Peptides for the Robust Induction of CTL Directed towards H-2Db in Complex with the Melanoma-Associated Epitope gp100

43. Supplementary Figure 6 from Design of Agonistic Altered Peptides for the Robust Induction of CTL Directed towards H-2Db in Complex with the Melanoma-Associated Epitope gp100

44. Supplementary Figure 5 from Design of Agonistic Altered Peptides for the Robust Induction of CTL Directed towards H-2Db in Complex with the Melanoma-Associated Epitope gp100

45. Timed Ang2-Targeted Therapy Identifies the Angiopoietin–Tie Pathway as Key Regulator of Fatal Lymphogenous Metastasis

46. Photon versus carbon ion irradiation: immunomodulatory effects exerted on murine tumor cell lines

47. The Outcome of Ex Vivo TIL Expansion Is Highly Influenced by Spatial Heterogeneity of the Tumor T-Cell Repertoire and Differences in Intrinsic In Vitro Growth Capacity between T-Cell Clones

48. Proimmunogenic impact of MEK inhibition synergizes with agonist anti-CD40 immunostimulatory antibodies in tumor therapy

49. The m6A-Related mRNA Signature Predicts the Prognosis of Pancreatic Cancer Patients

50. T cell-mediated elimination of cancer cells by blocking CEACAM6–CEACAM1 interaction

Catalog

Books, media, physical & digital resources